세계의 헤파리노이드 시장 : 분석과 예측(2023-2032년)

Global Heparinoid Market - Analysis and Forecast, 2023-2032

US $ 2,475 ￦ 3,408,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 3,825 ￦ 5,267,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 헤파리노이드 시장에 대해 조사했으며, 시장의 개요와 원재료별, 용도별, 제형별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 시장

• 세계 시장의 전망
• 업계의 전망
• 비즈니스 역학

제2장 세계의 헤파리노이드 시장, 원재료별

• Chondroitin Sulphates
• Dermatan Sulphate
• Heparitin Sulphate

제3장 세계의 헤파리노이드 시장, 용도별, (100만 달러), 2021-2032년

• 기회 평가
• 성장 점유율 매트릭스
• 의약품
• 식이보충제
• 스포츠 영양학
• 동물 사료
• 기타

제4장 세계의 헤파리노이드 시장, 제형별, (100만 달러), 2021-2032년

• 기회 평가
• 성장 점유율 매트릭스
• 분말
• 캡슐

제5장 세계의 헤파리노이드 시장, 지역별, (100만 달러), 2021-2032년

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제6장 시장(경쟁 벤치마킹과 기업 개요)

• 경쟁 구도
  • 주요 전략과 개발
  • 시장 점유율 분석
• 기업 개요
  • Merck KGaA
  • SEIKAGAKU CORPORATION
  • TSI Group Ltd.
  • Synutra Pure, Ltd.
  • Bioiberica S.A.U.
  • Kala Health Inc.
  • Beloorbayir Biotech Ltd
  • Sichuan Biosyn Pharmaceutical Co., Ltd
  • Seikagaku Corporation
  • Jiaxing Hengjie Bio-pharmaceutical LLC
• 기타 기업

KSA

영문 목차

영문목차

Market Overview:

The report offers a comprehensive view of the global heparinoid market, encompassing market size, growth drivers, challenges, and opportunities. It includes a historical analysis of market performance and explores the current market landscape.

The global heparinoid market is poised for continued growth, driven by ongoing research and development activities, strategic collaborations, and the introduction of novel products.

Market Segmentation:

Segmentation 1: by Raw Material

• Chondroitin Sulphates
• Dermatan Sulphate
• Heparitin Sulphate

Segmentation 2: by Application

• Pharmaceutical
• Dietary Supplements
• Sports Nutrition
• Animal Feed
• Others

Segmentation 3: by by Dosage Form

• Powder
• Capsule

Segmentation 4: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Data for each of these regions, along with country-level analyses, will be provided in the market study. The market analysis would be provided from the year 2022-2032.

How can this report add value to an organization?

Growth/Marketing Strategy: The global heparinoid market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategy for the companies has been a business expansion to strengthen their positions in the heparinoid market.

Competitive Strategy: A detailed competitive benchmarking of the players operating in the global heparinoid market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Some of the prominent names established in this market are:

Table of Contents

1. Market

• 1.1Global Market Outlook
  • 1.1.1. Product Definition
  • 1.1.2. Inclusion and Exclusion Criteria
  • 1.1.3. Key Findings
  • 1.1.4. Assumptions and Limitations
  • 1.1.5. Global Market Scenario
• 1.2. Industry Outlook
  • 1.2.1. Market Overview
  • 1.2.2. Key Trends
    • 1.2.2.1. Dosage Form
    • 1.2.2.2. New Products
  • 1.2.3. Patent Analysis
  • 1.2.4. Product Benchmarking
  • 1.2.5. Regulatory Scenario
• 1.3. Business Dynamics
  • 1.3.1. Impact Analysis
  • 1.3.2. Business Drivers
  • 1.3.3. Business Restraints
  • 1.3.4. Business Opportunities

2. Global Heparinoid Market (by Raw Material)

• 2.1. Chondroitin Sulphates
• 2.2. Dermatan Sulphate
• 2.3. Heparitin Sulphate

3. Global Heparinoid Market (by Application), $Million 2021-2032

• 3.1. Opportunity Assessment
• 3.2. Growth Share Matrix
• 3.3. Pharmaceutical
• 3.4. Dietary Supplements
• 3.5. Sports Nutrition
• 3.6. Animal Feed
• 3.7. Others

4. Global Heparinoid Market (by Dosage Form) $Million 2021-2032

• 4.1. Opportunity Assessment
• 4.2. Growth Share Matrix
• 4.3. Powder
• 4.4. Capsule

5. Global Heparinoid Market (by Region) $Million 2021-2032

• 5.1. North America Heparinoid Market
  • 5.1.1. Key Findings and Opportunity Assessment
  • 5.1.2. Market Dynamics
    • 5.1.2.1. Impact Analysis
  • 5.1.3. Sizing and Forecast Analysis
    • 5.1.3.1. North America Heparinoid Market (by Country)
      • 5.1.3.1.1. U.S.
      • 5.1.3.1.2. Canada
• 5.2. Europe Heparinoid Market
  • 5.2.1. Key Findings and Opportunity Assessment
  • 5.2.2. Market Dynamics
    • 5.2.2.1. Impact Analysis
  • 5.2.3. Sizing and Forecast Analysis
    • 5.2.3.1. Europe Heparinoid Market (by Country)
      • 5.2.3.1.1. Germany
      • 5.2.3.1.2. France
      • 5.2.3.1.3. U.K.
      • 5.2.3.1.4. Italy
      • 5.2.3.1.5. Spain
      • 5.2.3.1.6. Rest-of-Europe
• 5.3. Asia-Pacific Heparinoid Market
  • 5.3.1. Key Findings and Opportunity Assessment
  • 5.3.2. Market Dynamics
    • 5.3.2.1.1. Impact Analysis
  • 5.3.3. Sizing and Forecast Analysis
    • 5.3.3.1. Asia-Pacific Heparinoid Market (by Country)
      • 5.3.3.1.1. Japan
      • 5.3.3.1.2. China
      • 5.3.3.1.3. Australia
      • 5.3.3.1.4. India
      • 5.3.3.1.5. South Korea
      • 5.3.3.1.6. Rest-of-Asia-Pacific
• 5.4. Latin America Heparinoid Market
  • 5.4.1. Key Findings and Opportunity Assessment
  • 5.4.2. Market Dynamics
    • 5.4.2.1.1. Impact Analysis
  • 5.4.3. Sizing and Forecast Analysis
    • 5.4.3.1. Latin America Heparinoid Market (by Country)
      • 5.4.3.1.1. Brazil
      • 5.4.3.1.2. Mexico
      • 5.4.3.1.3. Rest-of-Latin America
• 5.5. Middle East and Africa Heparinoid Market
  • 5.5.1. Key Findings and Opportunity Assessment
  • 5.5.2. Market Dynamics
    • 5.5.2.1.1. Impact Analysis
  • 5.5.3. Sizing and Forecast Analysis

6. Markets (Competitive Benchmarking and Company Profiles)

• 6.1. Competitive Landscape
  • 6.1.1. Key Strategies and Developments
    • 6.1.1.1. Partnerships, Alliances, and Business Expansion
    • 6.1.1.2. Funding Activities
    • 6.1.1.3. New Offerings
    • 6.1.1.4. Mergers and Acquisitions
    • 6.1.1.5. Regulatory and Legal Activities
    • 6.1.1.6. Others (Promotional Activities)
  • 6.1.2. Market Share Analysis
• 6.2. Company Profiles
  • 6.2.1. Merck KGaA
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Product Portfolio
    • 6.2.1.3. Financials
    • 6.2.1.4. Recent Developments
    • 6.2.1.5. Analyst Perspective
  • 6.2.2. SEIKAGAKU CORPORATION
  • 6.2.3. TSI Group Ltd.
  • 6.2.4. Synutra Pure, Ltd.
  • 6.2.5. Bioiberica S.A.U.
  • 6.2.6. Kala Health Inc.
  • 6.2.7. Beloorbayir Biotech Ltd
  • 6.2.8. Sichuan Biosyn Pharmaceutical Co., Ltd
  • 6.2.9. Seikagaku Corporation
  • 6.2.10. Jiaxing Hengjie Bio-pharmaceutical LLC
• 6.3. Other Companies

List of company profiles is tentative it may change with the course of research.

^*Financials are provided for the public companies only.

관련자료